title: [ApoE polymorphisms and dopaminergic replacement therapy in Parkinson's disease].
abstract: BACKGROUND
  The expression of apolipoprotein E (apoE) polymorphisms has been proposed as a risk factor for early development of psychotic symptoms in patients with Parkinson's disease. The association between apoE polymorphisms and motor complications is controversial. The aim was to determine the association between apoE polymorphisms and its allele frequency with the development of complications secondary to dopaminergic replacement therapy.
  
  
  METHODS
  We evaluated 231 patients with the diagnosis of Parkinson's disease. The presence of motor complications secondary to treatment was determined by a neurologist, and the genotypification of apoE polymorphisms was performed. Descriptive statistics and chi-squared test were used.
  
  
  RESULTS
  Genotype ?3/?3 was expressed in 80.5 % of the sample; there was no association between genotype or allele frequency of apoE polymorphisms and the development of psychosis or dyskinesia. Patients who expressed the ?2 allele showed a tendency to develop motor fluctuations, but without reaching statistical significance (p = 0.08).
  
  
  CONCLUSIONS
  ApoE polymorphisms are not associated with the development of complications from dopaminergic replacement therapy.
authors.affiliation: Laboratorio Clínico de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Secretaría de Salud, Distrito Federal, México. mrodriguez@innn.edu.mx.
authors.forename: Amin
authors.initials: A
authors.lastname: Cervantes-Arriaga
authors.forename: Mayela
authors.initials: M
authors.lastname: Rodríguez-Violante
authors.forename: Paulina
authors.initials: P
authors.lastname: González-Latapí
authors.forename: David José
authors.initials: DJ
authors.lastname: Dávila-Ortiz de Montellano
authors.forename: Petra
authors.initials: P
authors.lastname: Yescas
authors.forename: Elisa
authors.initials: E
authors.lastname: Alonso-Vilatela
mesh_terms: D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001057:Apolipoproteins E / Q000235:genetics*; D003430:Cross-Sectional Studies; D015259:Dopamine Agents / Q000009:adverse effects* / Q000627:therapeutic use; D020820:Dyskinesias / Q000209:etiology*; D005260:Female; D005787:Gene Frequency; D005819:Genetic Markers; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D011110:Polymorphism, Genetic; D011618:Psychotic Disorders / Q000209:etiology*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D001057:Apolipoproteins E; D015259:Dopamine Agents; D005819:Genetic Markers
keywords: Apolipoproteins E; Dyskinesias; Genetic polymorphism; Movement disorder; Parkinson disease